This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanoff, H. K. Articles by Goldberg, R. M. Search for Related Content PubMed PubMed Citation Articles by Sanoff, H. K. Articles by Goldberg, R. M. Related Articles Related Correspondence Social Bookmarking                            What's this?

Managing Older Patients With Colorectal Cancer

Hanna Kelly Sanoff, Harry Bleiberg, Richard M. Goldberg

From the Department of Medicine, Division of Hematology-Oncology, University of North Carolina at Chapel Hill; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Institut Jules Bordet, Brussels, Belgium

Address reprint requests to Richard M. Goldberg, MD, Division of Hematology and Oncology, University of North Carolina, 3009 Old Clinic Bldg, CB 7305, Chapel Hill, NC 27599; e-mail: goldberg{at}med.unc.edu

Colorectal cancer (CRC) is predominantly a disease of older persons, and our population is aging. Physicians and their older patients commonly face the dilemma of whether or not to give/receive systemic chemotherapy for CRC. Evidence supports the safety and efficacy of systemic chemotherapy in fit older patients motivated enough to enroll onto clinical trials. Conversely, frail older patients are more likely to suffer adverse outcomes when faced with stressors and may not benefit from chemotherapy. However, the majority of patients are neither fit nor frail, and current evidence is insufficient to either quantify or qualify the benefit of chemotherapy for this intermediate group of patients. Thus, treatment decisions must be individualized based on each older person's physical state (eg, their function and degree of comorbidity) and values. Despite a growing body of data, a great deal of work is still needed to establish optimal strategies to care for patients diagnosed with cancer later in life.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Age Group–Specific Gap Between Treatment Cost of and Mortality Due to Breast and Colorectal Cancer
  Imre Boncz, Andor Sebestyén, István Pintér, József Betlehem, Ildikó Kriszbacher, Tibor Csere, László Mangel, and József Bódis
  JCO 2007 25: 4501-4502 [Full Text]

This article has been cited by other articles:

				T. R. Asmis, E. Powell, C. S. Karapetis, D. J. Jonker, D. Tu, M. Jeffery, N. Pavlakis, P. Gibbs, L. Zhu, D.- A. Dueck, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care Ann. Onc., July 5, 2010; (2010) mdq309v1. [Abstract] [Full Text] [PDF]

				R. B. Hines, C. Chatla, H. L. Bumpers, J. W. Waterbor, G. McGwin Jr, E. Funkhouser, C. S. Coffey, J. Posey, and U. Manne Predictive Capacity of Three Comorbidity Indices in Estimating Mortality After Surgery for Colon Cancer J. Clin. Oncol., September 10, 2009; 27(26): 4339 - 4345. [Abstract] [Full Text] [PDF]

				D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., January 1, 2009; 20(1): 5 - 16. [Abstract] [Full Text] [PDF]

				T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting Oncologist, August 1, 2008; 13(8): 876 - 885. [Abstract] [Full Text] [PDF]

				N. L. Keating, M. B. Landrum, C. N. Klabunde, R. H. Fletcher, S. O. Rogers, W. R. Doucette, D. Tisnado, S. Clauser, and K. L. Kahn Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity? J. Clin. Oncol., May 20, 2008; 26(15): 2532 - 2537. [Abstract] [Full Text] [PDF]

				I. Boncz, A. Sebestyen, I. Pinter, J. Betlehem, I. Kriszbacher, T. Csere, L. Mangel, and J. Bodis Age Group Specific Gap Between Treatment Cost of and Mortality Due to Breast and Colorectal Cancer J. Clin. Oncol., October 1, 2007; 25(28): 4501 - 4502. [Full Text] [PDF]

				H. Sanoff, H. Bleiberg, and R. Goldberg In Reply J. Clin. Oncol., October 1, 2007; 25(28): 4502 - 4503. [Full Text] [PDF]

				S. M. Lichtman, L. Balducci, and M. Aapro Geriatric Oncology: A Field Coming of Age J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823. [Full Text] [PDF]